Prognostic factors and survival in chronic myeloproliferative disorders;Prognostische faktoren und uberlebenszeiten bei chronischen myeloproliferativen erkrankungen (CMPE)

Pathologe

Volumn 21, Issue 1, 2000, Pages 63-72

  Kvasnicka, H M ^a   Thiele, J ^b   Schmitt Graeff, A ^b   Schaefer, H E ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

Bone marrow morphology; Chronic myeloproliferative disorders; Clinical findings; Survival

Indexed keywords

INTERFERON;

ADULT; AGE; AGED; ARTICLE; BONE MARROW EXAMINATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN DETERMINATION; HISTOLOGY; HUMAN; LEUKOCYTE COUNT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

EID: 0034117856     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002920050007     Document Type: Article

References (60)

1. Anger B, Haug U, Seidler R, Heimpel H (1989) Polycythemia vera. A clinical study of 141 patients. Blut 59:493-500
2. Anger B, Schmeiser T, Heimpel H, Robertson J, Sokal JE, Ganser A, Carbonell F (1990) Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model. Onkologie 13:109-114
3. Anger B, Seidler R, Haug U, Popp C, Heimpel H (1990) Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 75:228-234
4. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J (1996) Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk Lymphoma 22:149-160
5. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E (1988) A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397-401
6. Bilgrami S, Greenberg BR (1995) Polycythemia rubra vera. Semin Oncol 22:307-326
7. Brandt L, Anderson H (1995) Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol 54:21-26
8. Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 189:121-132
9. Cervantes F, Rozman C (1982) A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 60:1298-1304
10. Cervantes F, Lopez-Guillermo A, Bosch F Terol MJ, Rozman C, Montserrat E (1996) An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 57:286-291
11. Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E (1997) Identification of 'short-lived'and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635-640
12. Cervantes F, Rozman C, Feliu E (1989) Prognostic evaluation of initial bone marrow histopathological features in chronic granulocytic leukemia. cta Haematol 82:12-15
13. Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer lnst 89:1616-1620
14. Clough V, Geary CG, Hashmi K, Davson J, Knowlson T (1979) Myelofibrosis in chronic granulocytic leukaemia. Br J Haematol 42:515-526
15. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ (1987) The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59:1739-1743
16. Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Deminatti M, Bauters F (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855-859
17. Dickstein JI, Vardiman JW (1993) Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 99:513-525
18. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013-1018
19. Frezzato M, Ruggeri M, Castaman G, Rodeghiero F (1993) Polycythemia vera and essential thrombocythemia in young patients. Haematologica 78:11-17
20. Geary CG (1985) Clinical and hematological aspects of chronic myelofibrosis. In: Lewis SM (ed) Myelofibrosis. Pathophysiology and clinical management. Dekker, New York, pp 15-49
21. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22:15-29
22. Gruppo ltaliano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664
23. Hakama M, Hakulinen T (1977) Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis 30:585-597
24. Hakulinen T (1982) Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38:933-942
25. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858
26. Hasselbalch HC (1993) Idiopathic myelofibrosis-an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 23:124-138
27. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Reiter A, Hochhaus A (1997) Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Br J Haematol 97:76-85
28. Ivanyi JL, Mahunka M, Papp A, Kiss A, Jelek B (1994) Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system. Haematologia (Budap) 26:75-86
29. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8
30. Kelsey PR, Geary CG (1988) Sea-blue histiocytes and Gaucher cells in bone marrow of patients with chronic myeloid leukaemia. J Clin Pathol 41:960-962
31. Kvasnicka HM, Thiele J, Regn C, Zankovich R, Diehl V, Fischer R (1999) Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis. Ann Hematol 78:65-72
32. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R (1997) Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80:708-719
33. Lazzarino M, Morra E, Castello A, Inverardi D, Coci A, Pagnucco G, Magrini U, Zei G, Bernasconi C (1986) Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br J Haematol 64:227-240
34. Levis A, Marmont F, Ciocca Vasino MA, Jayme A, lnfelise V, Cametti G, Canta M, Resegotti L (1986) Peripheral erythroid precursor and prognosis in chronic granulocytic leukemia. Cancer 58:229-233
35. Michiels JJ (1999) Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 5:30-36
36. Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39
37. Najean Y, Dresch C, Rain JD (1994) The very long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 86:233-235
38. Ohnishi K, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Ohno R (1998) A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia.The Kouseisho Leukemia Study Group. Leuk Res 22:779-786
39. Ozen S, Ferhanoglu B, Senocak M, Tuzuner N (1997) Idiopathic myelofibrosis (agnogenic myeloid metaplasia): clinicopathological analysis of 32 patients. Leuk Res 21:125-131
40. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A (1997) Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98:96-102
41. Rozman C, Cervantes F, Feliu E (1989) Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view? Eur J Haematol 42:150-154
42. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663
43. Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, D'Amico S, Cinciripini A, Leoni P (1994) Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 68:205-212
44. Schaefer HE (1995) Die histologische Bearbeitungstechnik von Beckenkammbiopsien auf der Basis von Entkalkung und Paraffineinbettung unter Berücksichtigung osteologischer und hämatologischer Fragestellungen. Pathologe 16:11-27
45. Sokal JE.Baccarani M, Russo D, Tura S (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49-61
46. Soll E, Massumoto C, Clift RA, Buckner CD, Appelbaum FR, Storb R, Sale G, Hackman R, Martin P (1995) Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 86:4667-4673
47. The Benelux CML Study Group (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 91:2713-2721
48. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1993) Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. Leuk Lymphoma 11:67-71
49. Thiele J, Kvasnicka H, Zankovich R, Fischer R, Diehl V (1991) Parameters of predictive value in chronic myeloid leukemia -the prognostic impact of histopathological variables in a multivariate regression analysis. Leuk Lymphoma 4:63-74
50. Thiele J, Hoefer M, Kvasnicka HM, Bertsch HP, Zankovich R, Fischer R (1993) Erythropoiesis in CML-immunomorphometric quantification, PCNA-reactivity, and influence on survival. Hematol Pathol 7:239-249
51. Thiele J, Kvasnicka HM, Titius BR, Parpert U, Nebel R, Zankovich R, Dienemann D, Stein H, Diehl V, Fischer R (1993) Histological features of prognostic significance in CML-an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann Hematol 66:291-302
52. Thiele J, Kvasnicka HM, Niederle N, Kloke O, Schmidt M, Lienhard H, Zirbes T, Meuter RB, Leder LD, Fischer R (1995) Clinical and histological features retain their prognostic impact under interferon therapy of CML: a pilot study. Am J Hematol 50:30-39
53. Thiele J, Kvasnicka HM, Niederle N, Zirbes TK, Schmidt M, Dammasch J, Meuter BR, Leder LD, Kloke O, Diehl V (1995) The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML-a comparative morphometric study on sequential trephine biopsies. Ann Hematol 70:121-128
54. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R (1996) Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 22:303-317
55. Thiele J, Kvasnicka HM, Zirbes TK, Flucke U, Niederle N, Leder LD, Diehl V, Fischer R (1998) Impact of clinical and morphological variables in classification and regression tree-based survival (CART) analysis of CML with special emphasis on dynamic features. Eur J Haematol 60:35-46
56. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 33:207-218
57. Varki A, Lottenberg R, Griffith R, Reinhard E (1983) The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 62:353-371
58. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4-9
59. Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63:101-106
60. Zankovich R, Thiele J, Fiessler WD, Fischer R, Diehl V (1987) Prognostic parameters in polycythaemia vera rubra. Correlations of clinical and histomorphological features in 60 patients. Med Klin 82:889-894, 927